<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00603317</url>
  </required_header>
  <id_info>
    <org_study_id>P051056</org_study_id>
    <nct_id>NCT00603317</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic Drug Interaction Between Warfarin and Amoxicillin-clavulanic Acid</brief_title>
  <acronym>INWARA</acronym>
  <official_title>Pharmacodynamic Drug Interaction Between Warfarin and Amoxicillin-clavulanic Acid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several case reports indicate that the use of the antibiotic combination amoxicillin and
      clavulanic acid (AM-CLAVAC) can interact with warfarin pharmacodynamics. However, fever per
      se might also be responsible of these warfarin overdose reports, as well as the use of high
      dose paracetamol.

      The aim of the present study is to determine if AM-CLAVAC can increase the pharmacodynamics
      of warfarin among patients at steady state Double blinded cross over controlled study vs
      placebo performed in 12 evaluable patients treated with warfarin with an INR target 2 to 3
      and a stable INR and a stable dose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double blinded cross over controlled study vs placebo performed in 12 evaluable patients
      treated with warfarin with an INR target 2 to 3 and a stable INR and a stable dose

      One period : seven consecutive days of amoxicillin(2g twice daily)- clavulanic acid (125 mg
      twice daily) association Wash out period of at least 4 weak with the return to a stable INR
      and warfarin dose One period : seven consecutive days of placebo twice daily

      Main outcome INR delta Day7-Day
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>INR at day one and seven (delta Day7-Day1)</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>% of patients with an INR&gt;3.5 during each study period mean INR during each study period effect of VKORC1 genetic polymorphism trough blood concentrations of S and R warfarin at day1 and day7 (delta) during each study period</measure>
    <time_frame>7 days for each period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Oral Anticoagulation</condition>
  <condition>Deep Venous Thrombosis</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Order 1 : Firstly Amoxicillin-Acid clavulanic, and Secondly Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Order 2 : Firstly Placebo, and Secondly Amoxicillin-Acid clavulanic</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Firstly : Amoxicillin-Clavulanic acid and secondly : Placebo</intervention_name>
    <description>Amoxicillin : 2g twice daily Clavulanic acid : 125 mg twice daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Firstly : Placebo and secondly : Amoxicillin-Clavulanic acid</intervention_name>
    <description>Amoxicillin : 2g twice daily Clavulanic acid : 125mg twice daily seven consecutive days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients treated with warfarin (target INR 2 to 3)

          -  stable anticoagulation (3 consecutive INR in the target)

          -  stable dose

          -  no infection

          -  normal CRP

          -  age &gt;18 years

          -  normal transaminase levels

        Exclusion Criteria:

          -  drug allergy

          -  penicillin allergy

          -  Alzheimer

          -  cancer

          -  thyroid disease

          -  gastro intestinal chronic disease

          -  frequent nausea or vomiting

          -  Cirrhosis

          -  chronic renal failure (GFR&lt;60 ml/min)

          -  frequent intake of paracetamol or NSAID

          -  addict to drugs or alcool

          -  St John's wort treatment or grapefruit juice intake

          -  concomitant drugs (amiodarone, cimetidine, SSRI, clofibrate, fenofibrate, diltiazem,
             fluconazole, itraconazole, isoniazide, voriconazole, métronidazole, miconazole ,
             omeprazole, glucocorticoids, zileuton, ritonavir, rifampicin, carbamazepine,
             phenytoin, phenobarbital)

          -  antibiotic use during the 3 last weeks

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephane MD MOULY, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Lariboisière - Service de médecine interne</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2008</study_first_submitted>
  <study_first_submitted_qc>January 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2008</study_first_posted>
  <last_update_submitted>July 9, 2010</last_update_submitted>
  <last_update_submitted_qc>July 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Valerie MILLUL</name_title>
    <organization>Department Clinical Reseach of Developpement</organization>
  </responsible_party>
  <keyword>Warfarin</keyword>
  <keyword>Drug interaction</keyword>
  <keyword>Pharmacogenetics</keyword>
  <keyword>Amoxicillin</keyword>
  <keyword>Clavulanic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

